Is MCF2L rs11842874 AA associated with higher osteoarthritis risk and hip or knee pain expression?

The MCF2L rs11842874 genetic variant is an established susceptibility locus for osteoarthritis, with emerging biological pathways linking it directly to joint pain sensitization.

Genetic Association and Osteoarthritis Risk

• Large-scale genome-wide association studies (GWAS) robustly link the A risk allele of rs11842874 to an increased risk of hip and knee osteoarthritis.
• Individuals with the homozygous AA genotype carry two copies of this variant, experiencing a modest but statistically significant elevation in susceptibility, with a per-allele odds ratio of approximately 1.17 (95% CI: 1.11–1.23; p ≈ 2.1 × 10⁻⁸).

Biological Mechanisms of Pain Expression

• The risk-conferring AA genotype acts as a cis-expression quantitative trait locus (cis-eQTL) that increases MCF2L gene expression specifically in the synovial membrane.
• Elevated synovial MCF2L expression regulates Nerve Growth Factor (NGF) signaling.
• NGF is a primary mediator of peripheral nociception and joint hyperalgesia; therapeutic blockade of this pathway is clinically proven to reduce osteoarthritis pain, making the genetic influence on pain expression highly plausible.

Clinical Considerations and Limitations

• Although the biological mechanism linking MCF2L to NGF-mediated pain is robust, direct clinical association studies are limited.
• There is currently a lack of quantitative data directly correlating the AA genotype with clinical pain metrics, such as the Visual Analog Scale (VAS) or Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores. The variant functions primarily as a marker of disease susceptibility rather than a clinical tool to predict pain severity.

Bottom line

• The MCF2L rs11842874 AA genotype statistically elevates hip and knee osteoarthritis risk and is mechanistically linked to joint pain via synovial NGF regulation, though direct clinical utility for predicting pain severity requires further quantitative validation.